Acyclovir & Levothyroxine Interaction

Acyclovir is an antiviral medication used primarily for herpes simplex and varicella-zoster virus infections. Levothyroxine is the standard thyroid hormone replacement for hypothyroidism. While these medications are not commonly associated with a major drug interaction, there are clinical considerations when they are used concurrently.

Case reports have suggested that acyclovir and valacyclovir may transiently affect thyroid function tests, potentially complicating the management of patients on levothyroxine replacement therapy. The mechanism is not fully established, but may relate to effects on thyroid hormone binding or metabolism.

The interaction is classified as minor because clinically significant outcomes are rare, but awareness is important for clinicians interpreting thyroid function tests in patients receiving antiviral therapy.

The exact pharmacological mechanism is not well-characterized. Acyclovir is primarily eliminated through renal excretion and does not undergo significant hepatic metabolism. Levothyroxine is metabolized by deiodination in the liver, kidneys, and other tissues, and is also conjugated via glucuronidation and sulfation.

Theoretical mechanisms for interaction include transient effects of viral illness on thyroid function (sick euthyroid syndrome) confounding the assessment, potential effects of acyclovir on thyroid hormone protein binding, and possible subtle effects on deiodination pathways. The clinical data supporting a direct pharmacological interaction are limited.

The clinical significance is low for most patients. Short courses of acyclovir for acute herpes infections are unlikely to meaningfully affect levothyroxine therapy. The primary concern is misinterpretation of thyroid function tests obtained during acute illness and antiviral treatment.

Patients who are critically ill or have severe viral infections may experience non-thyroidal illness syndrome (sick euthyroid syndrome), where thyroid function tests can be abnormal without true thyroid dysfunction. This is more related to the illness than to acyclovir itself.

For patients on chronic suppressive acyclovir therapy (e.g., for recurrent herpes), the interaction risk remains low, but periodic thyroid function monitoring is reasonable as part of routine levothyroxine management.

No specific dose adjustments are typically required when acyclovir is prescribed to patients on levothyroxine. Patients should continue their levothyroxine at the same dose and timing, taking it on an empty stomach in the morning as usual.

If thyroid function tests are needed during acyclovir therapy, clinicians should interpret results in the context of acute illness and antiviral treatment. Abnormal results may warrant repeat testing 4-6 weeks after completing the antiviral course rather than immediate levothyroxine dose adjustment.

Patients on chronic suppressive acyclovir should maintain their regular thyroid function monitoring schedule, typically every 6-12 months for stable hypothyroid patients.